Overview

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Evaluation of safety and tolerability of a single injection of NOVA63035 "Corticosteroid" administered at one of four doses in patients with diabetic macular edema (DME) secondary to diabetic retinopathy
Phase:
Phase 1
Details
Lead Sponsor:
Santen SAS